source
- AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart diseaseResults published in NEJM raised questions about the benefits “silencer” medications provide on top of standard therapies for TTR cardiomyopathy and amplified investor pressure on Alnylam.
- Federal autism advisory panel reaffirms discredited theories amid vaccine controversyAt a recent meeting of the federal autism advisory committee, members again promoted theories linking vaccines to autism that have been repeatedly disproven by scientific studies. The discussion c…